Baiji Shenzhou announced the commercial listing of Baiyueda in China.

On January 14th, BeiGene announced that its independently developed first-in-class novel BCL2 inhibitor, Brukinsa, has started supply on January 13th, and the first batch of drugs will be available in 70 cities nationwide.